Tackling regulated cell death yields enhanced protection in lung grafts
- PMID: 37649611
- PMCID: PMC10465232
- DOI: 10.7150/thno.87375
Tackling regulated cell death yields enhanced protection in lung grafts
Abstract
Background: Effective preservation strategies to ameliorate lung graft ischaemia injury are needed to rescue 'extended criteria' or 'marginal' lung grafts, and to improve recipient outcomes after transplantation. Methods: Lung grafts from male Lewis rats were extracted after 40 min of cardiocirculatory death, and healthy human lung tissues were collected from patients undergoing a lobectomy. Lung samples were then preserved in a 4°C preservation solution supplemented with 0.1 nM Dexmedetomidine (Dex, α2-adrenoceptor agonist) for 16 h. In vitro, human lung epithelial A549 cells were preserved in the 4°C preservation solution with 0.1 nM Dex for 24 h, then re-cultured in the cell culture medium at 37°C to mimic the clinical scenario of cold ischaemia and warm reperfusion. Lung tissues and cells were then analysed with various techniques including western blot, immunostaining and electron microscope, to determine injuries and the protection of Dex. Results: Prolonged warm ischaemia after cardiocirculatory death initiated Rip kinase-mediated necroptosis, which was exacerbated by cold storage insult and enhanced lung graft injury. Dex supplementation significantly reduced necroptosis through upregulating Nrf2 activation and reducing oxidative stress, thereby significantly improving lung graft morphology. Dex treatment also attenuated endoplasmic reticulum stress, stabilised lysosomes and promoted cell membrane resealing function, consequently reducing cell death and inflammatory activation after hypothermic hypoxia-reoxygenation in A549 cells. Conclusions: Inhibition of regulated cell death through Dex supplementation to the graft preservation solution improves allograft quality which may aid to expand the donor lung pool and enhance lung transplant outcomes per se.
Keywords: Dexmedetomidine.; Donation after cardiocirculatory death; Ischaemia reperfusion injury; Lung transplantation; Regulated cell death.
© The author(s).
Conflict of interest statement
Competing Interests: Some data have been filed for a patent application.
Figures
Similar articles
-
Preservation solution supplemented with biliverdin prevents lung cold ischaemia/reperfusion injury.Eur J Cardiothorac Surg. 2012 Dec;42(6):1035-41. doi: 10.1093/ejcts/ezs298. Epub 2012 May 30. Eur J Cardiothorac Surg. 2012. PMID: 22648925 Free PMC article.
-
Supplemental hydrogen sulphide protects transplant kidney function and prolongs recipient survival after prolonged cold ischaemia-reperfusion injury by mitigating renal graft apoptosis and inflammation.BJU Int. 2012 Dec;110(11 Pt C):E1187-95. doi: 10.1111/j.1464-410X.2012.11526.x. Epub 2012 Nov 16. BJU Int. 2012. PMID: 23157304
-
Dexmedetomidine and argon in combination against ferroptosis through tackling TXNIP-mediated oxidative stress in DCD porcine livers.Cell Death Discov. 2024 Jul 11;10(1):319. doi: 10.1038/s41420-024-02071-7. Cell Death Discov. 2024. PMID: 38992027 Free PMC article.
-
Osteopontin mediates necroptosis in lung injury after transplantation of ischaemic renal allografts in rats.Br J Anaesth. 2019 Oct;123(4):519-530. doi: 10.1016/j.bja.2019.05.041. Epub 2019 Jun 28. Br J Anaesth. 2019. PMID: 31262508
-
Liver graft preservation methods during cold ischemia phase and normothermic machine perfusion.World J Gastrointest Surg. 2019 Mar 27;11(3):126-142. doi: 10.4240/wjgs.v11.i3.126. World J Gastrointest Surg. 2019. PMID: 31057698 Free PMC article. Review.
References
-
- Valapour M, Lehr CJ, Skeans MA, Smith JM, Uccellini K, Goff R. et al. OPTN/SRTR 2018 Annual Data Report: Lung. Am J Transplant. 2020;20(Suppl s1):427–508. - PubMed
-
- Reeb J, Keshavjee S, Cypel M. Expanding the lung donor pool: advancements and emerging pathways. Curr Opin Organ Transplant. 2015;20:498–505. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous